FLUCONAZOLE/CLARITHROMYCIN/RIFABUTIN EFFECTS ON HYDROXYLAMINE PHARMACOKINETICS

氟康唑/克拉霉素/利福布丁对羟胺药代动力学的影响

• 批准号: 6246769
• 负责人: STEPHEN P RAFFANTI
• 金额: $ 3.1万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-27 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246769
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clarithromycin; clearance rate; clinical research; combination chemotherapy; cytochrome P450; drug interactions; drug metabolism; enzyme induction /repression; fluconazole; human subject; hydroxylamine; pharmacokinetics; rifabutin

To determine: (1) the effect of co-administration of fluconazole and rifabutin, together and alone on the total clearance and hydroxylamine formation clearance of SMX and dapsone in patients with HIV infection. (2) if the degree of inhibition of the formation of the hydroxylamines of SMX and dapsone is altered by induction of cytochrome p450 by rifabutin. (3) if the degree of inhibition of the formation of the hydroxylamines of SMX and dapsone by fluconazole and clarithromycin separately and together is of a magnitude similar to that predicted from in vitro data.

确定：（1）氟康唑共同给药的影响 利法伯丁素，共同清除和羟胺单独 HIV感染患者的SMX和Dapsone的形成清除率。 （2）如果抑制羟胺的形成程度 Smx和Dapsone的诱导通过细胞色素P450的改变而改变 利法布丁。 （3）如果抑制程度 氟康唑和克拉霉素的SMX和Dapsone的羟胺 分别和一起的大小类似于 体外数据。